Medicare expands free diabetes education, removes copays for beneficiaries

What it does

This bill expands Medicare coverage for diabetes self-management training by guaranteeing 10 initial hours of education (individual or group) plus 2 additional hours annually, with no cost-sharing to beneficiaries, and removes physician-imposed limits on medically necessary services. It also mandates a pilot program testing virtual (online) diabetes training delivery starting January 1, 2026, to measure health outcomes and cost savings.

Why we flagged it

The bill's core function is to expand Medicare coverage and reduce cost-sharing for a specific preventive/management service (diabetes education). It is a straightforward entitlement expansion, not a tax provision, deregulation, or industry carve-out.

What the text implies

• Removal of physician-imposed quantity limits (if deemed medically necessary) could increase utilization and Medicare spending beyond the guaranteed hours, with no explicit budget cap.
• Virtual delivery pilot may shift training from in-person certified educators to web-based programs, potentially affecting employment in diabetes education workforce.
• Pilot program results (due ~2027–2028) may inform broader telehealth coverage policy across other chronic conditions, setting precedent for virtual-first care models.
• Cost-sharing elimination (100% coverage) may increase demand among beneficiaries who previously self-rationed due to copay burden, with downstream effects on Medicare expenditure.

Who it affects

Medicare beneficiaries with diabetes gain guaranteed access to diabetes education without copays or deductibles, reducing out-of-pocket costs and improving disease management. The pilot program tests virtual delivery to reach rural and underserved populations. The primary beneficiary is the patient population, not industry.

Who stands to gain

• diabetes education providers and certified diabetes educators
• telehealth platforms and digital health vendors
• pharmaceutical companies (indirectly, via improved medication adherence)

Named in the bill

Medicare (Title XVIII), Social Security Act Section 1861, Section 1115A (Center for Medicare & Medicaid Innovation), Secretary of Health and Human Services, Certified diabetes educators, Bristol Myers Squibb (BMY), Gilead Sciences (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ)

Where it stands

4 cosponsors: 2 Democrats, 1 Independents, 1 Republicans.

• Jun 2, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jun 2, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 2 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $174,615 in lobbying spend. A filing names 8 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Jeanne Shaheen, the sponsor, reported $-12,050 in PAC receipts in the 2026 cycle.

• Academy of Nutrition and Dietetics (formerly As American Dietetic Association) — $154,615 on 1 filing
• Association of Diabetes Care & Education Specialists (f/k/a Aade) — $20,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.